Matinas BioPharma FY26 Q2 net loss narrows to $3.25 million

• Matinas BioPharma narrowed its net loss to USD 3.25 million for the six months ended June 30, 2026.
• General and administrative expense dipped 5.62% to USD 3.49 million, driven by lower headcount and lease costs.
• Net cash used in operating activities eased to USD 3.44 million; cash and cash equivalents totaled USD 761,000 at June 30.
• Entered a business combination agreement with GH Power; expects GH Power’s business to become the combined company’s primary focus.
• Signed a stock sale with Azurity for Nanotechnologies, with up to USD 21.5 million consideration and a mid-single-digit royalty on MAT2203.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037748), on August 13, 2026, and is solely responsible for the information contained therein.